收稿日期: 2018-08-31
网络出版日期: 2018-12-18
基金资助
国家自然科学基金(81302586)
Effects of integrin metalloproteinases on osteogenic differentiation
Received date: 2018-08-31
Online published: 2018-12-18
Supported by
Supported by the National Natural Science Foundation of China(81302586)
目的: 探讨去整合素金属蛋白酶(a disintegrin and metalloproteinase, ADAM)9、15、17在骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMMSCs)成骨分化中的作用。方法:分离ADAM9、ADAM15、ADAM17的条件基因敲除小鼠及野生型(wild type,WT)小鼠的BMMSCs,培养刺激其分化为成骨细胞。比色法测定成骨标志碱性磷酸酶(alkaline phosphatase,ALP)活性,实时荧光定量PCR检测成骨早期转录因子Runx、Osterix,茜素红染色分析成骨矿物质形成情况。 结果:在无刺激的对照培养下,ADAM9组(8.08±0.34)、ADAM15组(6.46±3.40)、ADAM17(9.30±2.30)组的ALP活性与WT组(9.44±2.50)相比差异无统计学意义(P均>0.05)。用骨形态发生蛋白质2(bone morphogenic protein 2, BMP2)刺激培养, ADAM9组(14.22±3.25)、ADAM15组(10.14±2.40)的ALP均小于WT组(20.89±3.40), 差异有统计学意义(P均<0.05),而ADAM17组(23.56±2.50)虽大于WT组(20.89±3.40),但差异无统计学意义(P>0.05)。用成骨培养基(osteogenic induction medium, OST)刺激培养,ADAM9组(9.63±1.00)、ADAM15组(7.75±1.30)的ALP均小于WT组(12.97±1.30), 而ADAM17组(20.09±1.68)大于WT组(12.97±1.30),差异均有统计学意义(P均<0.05)。同样,BMP2与OST联合刺激培养后检测ALP,ADAM9组(15.75±1.30)、ADAM15组(12.43±1.30)均小于WT组(26.15±1.50),而ADAM17组(29.55±2.10)大于WT组,差异均有统计学意义(P均<0.05)。Runx2表达,在无刺激的对照培养下,ADAM9组(2.02±0.24)、ADAM15组(3.09±0.19)、ADAM17组(3.89±0.91)分别与WT组(2.02±0.21)相比差异均无统计学意义(P均>0.05);BMP2刺激培养后ADAM9组(7.00±0.23)、ADAM15组(6.04±0.23)均小于WT组(12.6±0.23),而ADAM17组(18.52±1.39)大于WT组,差异均有统计学意义(P均<0.05)。Osterix表达,在无刺激的对照培养下,ADAM9组(9.60±3.87)、ADAM17组(12.4±3.00)与WT组(10.9±1.10)比较差异均无统计学意义(P均>0.05),但ADAM15组(6.50±1.51)低于WT组(10.9±1.10), 差异有统计学意义(P<0.05);BMP2刺激培养后ADAM9组(39.20±3.23)、ADAM15组(20.50±4.80)均小于WT组(60.3±5.93), 而ADAM17组(80.2±3.30)大于WT组,差异均有统计学意义(P均<0.05)。茜素红染色,无刺激组未见明显橘红色团块,BMP2、OST、OST+BMP2刺激培养条件下各实验组均可见局部钙化结节形成,但量化分析差异无统计学意义(P>0.05)。 结论:ADAM9、15、17参与了BMMSCs的成骨分化,为调节BMMSCs成骨分化提供了新靶点。
刘霞 , 李英妮 , 孙晓麟 , 彭清林 , 卢昕 , 王国春 . 去整合素金属蛋白酶对成骨分化的影响[J]. 北京大学学报（医学版）, 2018 , 50(6) : 962 -967 . DOI: 10.19723/j.issn.1671-167X.2018.06.004
Objective: To study the effects of disintegrin and metalloproteinase (ADAM)9, 15 and 17 on the osteogenic differentiation of bone marrow mesenchymal stem cells (BMMSCs).Methods: BMMSCs of ADAM9, ADAM15, ADAM17 conditional knockout mice and wild type mice (WT) were induced and cultured. Alkaline phosphatase (ALP) activity was measured by colorimetry, early osteogenic transcription factors Runx and Osterix were detected by Real-time PCR, and mineral formation was analyzed by alizarin red staining. Results:ALP activity was lower in ADAM9 group (8.08±0.34), ADAM15 group (6.46±3.40), ADAM17 group (9.30±2.30) than that in WT group (9.44±2.50), but there was no significant difference (P>0.05). Stimulated with bone morphogenetic protein 2(BMP2),there was significant difference (P<0.05) between ADAM9 group (14.22±3.25), ADAM15 group (10.14±2.40) and WT group (20.89±3.40), and ADAM 17 group (23.56±2.50) was higher than WT group (20.89±3.40), but no significant difference (P>0.05).Similarly, cultured by osteogenic induction medium (OST), compared with WT group(12.97±1.30), ADAM9 group(9.63±1.00) and ADAM15 group(7.75±1.30)were lower,ADAM17 group (20.09±1.68) was higher, and the difference was statistically significant (P<0.05). Using stimulated culture by BMP2 and OST combined , ADAM9 group (15.75±1.30), ADAM 15 group (12.43±1.30) were less than WT group (26.15 ±1.50), while ADAM17 group (29.55±2.10) was higher than WT group were statistically significant (P<0.05). The expression of Runx2 in ADAM9 group (2.02±0.24), ADAM15 group (3.09±0.19), ADAM17 group (3.89±0.91) had no significant difference compared with WT (2.02±0.21) group (P>0.05). ADAM9 group stimulated by BMP2 (7.00±0.23), ADAM15 group (6.04±0.23) were lower than WT group (12.6±0.23), ADAM17 group (18.52±1.39) was higher than WT group (12.6±0.23), and the difference was statistically significant (P<0.05).In non-stimulating culture,there was no significant difference in Osterix expression between ADAM9 group (9.60±3.87) , ADAM17 group (12.40±3.00) and WT group (10.9±1.10, P>0.05),but in ADAM15 group (6.50±1.51) it was slightly lower than that in WT group (P<0.05). After BMP2 stimulation, ADAM9 group (39.20±3.23) and ADAM15 group (20.50±4.80) were less than WT group (60.30±5.93), while ADAM17 group (80.20±3.30) was higher than WT group (P<0.05). Alizarin red staining showed no obvious orange-red mass in the non-induction group. Local calcified nodules could be seen in the BMP2, OST, OST + BMP2 induction culture conditions in all the experimental groups, but there was no significant difference in quantitative analysis (P>0.05). Conclusion: ADAM9, 15, 17 took part in the osteogenic differentiation of BMMSCs, and provided new targets for its regulation.
| [1] | Reiss K, Saftig P . The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: Physiological and cellular functions[J]. Semin Cell Dev Biol, 2009,20(2):126-137. |
| [2] | Edwards DR, Handsley MM, Pennington CJ . The ADAM metalloproteinases[J]. Mol Aspects Med, 2008,29(5):258-289. |
| [3] | Walkiewicz K, Nowakowska-Zajdel E, Kozie? P , et al. The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer[J]. Cent Eur J Immunol, 2018,43(1):109-113. |
| [4] | Horowitz JD, Liu S . ADAM-15 and glycocalyx shedding: a new perspective on sepsis-related vasomotor dysfunction[J]. Cardiovasc Res, 2018,114(13):1694-1695. |
| [5] | Komiya K, Enomoto H, Inoki I , et al. Expression of ADAM15 in rheumatoid synovium: up-regulation by vascular endothelial growth factor and possible implications for angiogenesis[J]. Arthritis Res Ther, 2005,7(6):R1158-1173. |
| [6] | Govoni KE, Amaar YG, Kramer A , et al. Regulation of insulin-like growth factor binding protein-5, four and a half lim-2, and a disintegrin and metalloprotease-9 expression in osteoblasts[J]. Growth Horm IGF Res, 2006,16(1):49-56. |
| [7] | Karadag A, Zhou M, Croucher PI . ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v) beta5 integrin[J]. Blood, 2006,107(8):3271-3278. |
| [8] | Ishii S, Isozaki T, Furuya H , et al. ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion[J]. Arthritis Res Ther, 2018,20(1):159. |
| [9] | Haxaire C, Hakobyan N, Pannellini T , et al. Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNFα pathway[J]. Blood, 2018,132(10):1064-1074. |
| [10] | Verrier S, Hogan A , McKie N, et al. ADAM gene expression and regulation during human osteoclast formation[J]. Bone, 2004,35(1):34-46. |
| [11] | Primakoff P, Myles DG . The ADAM gene family: surface proteins with adhesion and proteinase activity[J]. Trends Genets, 2000,16(2):83-87. |
| [12] | Stone AT, Kroeger M, Amysang QX . Structure-function analysis of the adam family of disintegrin-like and metalloproteinase-containing p roteins[J]. J Protein Chem, 1999,18(4):447-465. |
| [13] | Seals DF, Courtneidge SA . The ADAMs family of metalloprotea-ses: multidomain proteins with multiple functions[J]. Genes Dev, 2003,17(1):7-30. |
| [14] | Hall KC, Hill D, Otero M , et al. ADAM17 controls endochondral ossification by regulating terminal differentiation of chondrocytes[J]. Mol Cell Biol, 2013,33(16):3077-3090. |
| [15] | Saito K, Horiuchi K, Kimura T , et al. Conditional inactivation of TNFα-converting enzyme in chondrocytes results in an elongated growth plate and shorter long bones[J]. PLoS One, 2013,8(1):e54853. |
| [16] | Zunke F, Rose-John S . The shedding protease ADAM17: Physio-logy and pathophysiology[J]. Biochim Biophys Acta Mol Cell Res, 2017,1864(11 Pt B):2059-2070. |
| [17] | Araya HF, Sepulveda H, Lizama CO , et al. Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2[J]. J Cell Biochem, 2018,119(10):8204-8219. |
| [18] | Horiuchi K, Kimura T, Miyamoto T , et al. Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis and increased granulopoiesis via dysregulation of IL-17 and G-CSF[J]. J Immunol, 2009,182(4):2093-2101. |
/
| 〈 |
|
〉 |
